What does HAMPHARMA do?

HAMPHARMA is a logistics company in Tessenderlo-Ham. Private Limited, started on 1 July 1982, 1 establishment.

What is the address of HAMPHARMA?

The registered office of HAMPHARMA is located at Bevrijdingsstraat 32, 3945 Tessenderlo-Ham.

Is HAMPHARMA still active?

Yes. According to the CBE (29 October 2026) HAMPHARMA is active, legal situation “Normale toestand”, started on 1 July 1982.

Is HAMPHARMA registered on Peppol?

Yes, HAMPHARMA is registered on the Peppol network with ID 0208:0423277613.

What is the enterprise number of HAMPHARMA?

The enterprise number of HAMPHARMA is BE0423277613.

When was HAMPHARMA founded?

HAMPHARMA was founded on 1 July 1982.

Who are the directors of HAMPHARMA?

According to the 2025 annual accounts, the directors of HAMPHARMA are: Denayer Danielle BV.

Is HAMPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 1 July 1982; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did HAMPHARMA make in 2025?

HAMPHARMA posted a profit after taxes of € 143,531 in financial year 2025.

What is the revenue of HAMPHARMA?

As a small company, HAMPHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 503,961.

How much does an employee at HAMPHARMA earn?

The average wage cost per full-time employee at HAMPHARMA was € 65,700 in 2025: staff costs of € 177,314 for 2.7 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does HAMPHARMA have?

According to the 2025 annual accounts, HAMPHARMA has 2.7 full-time equivalents (FTE).

HAMPHARMA (Private Limited) - Tessenderlo-Ham

Dossier HAMPHARMA, printed on 29 October 2026 from databakkes.be/en/0423277613/hampharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

HAMPHARMA from Tessenderlo-Ham, company number BE0423277613, closed financial year 2025 with a result of € 143,531 after tax. For that financial year HAMPHARMA recorded a gross margin of € 503,961 and equity of € 30,800. Compared with financial year 2024, the result moved from € 218,642 to € 143,531. The company is profitable. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 27, 2026.

What it is worth Growing

€ 30,800

▲ 3% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 143,531

▼ 34% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 303,758

▲ 6% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 142,500 paid out

99 % of the profit went to the shareholders, mostly to Denayer Danielle (100 % of the shares). That is where the money ends up.

People and assets in 2025

Full-time equivalents

2.7

▼ 0.1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 177,314

▲ 10% vs 2024

€ 65,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 19,528

▲ 63% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 12 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 1.3 million

▲ 23% vs 2024

€ 104,968 is repaid this year. At this pace the long-term loan is gone in ≈ 12 years.

Owed to suppliers

€ 119,727

▲ 22% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Wages and social charges

€ 31,792

▲ 28% vs 2024

Wages, holiday pay and social contributions still to pay. No outstanding taxes.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 421,455 Gross margin 2022: € 421,455 First fiscal year in the series	€ 472,240 Gross margin 2023: € 472,240 ▲ 12% vs 2022 (€ 421,455) Favourable step	€ 485,382 Gross margin 2024: € 485,382 ▲ 3% vs 2023 (€ 472,240) Favourable step	€ 503,961 Gross margin 2025: € 503,961 ▲ 4% vs 2024 (€ 485,382) Favourable step	▲ 4%
Profit after taxes	€ 272,604 Profit after taxes 2022: € 272,604 First fiscal year in the series	€ 298,117 Profit after taxes 2023: € 298,117 ▲ 9% vs 2022 (€ 272,604) Favourable step	€ 218,642 Profit after taxes 2024: € 218,642 ▼ 27% vs 2023 (€ 298,117) Unfavourable step	€ 143,531 Profit after taxes 2025: € 143,531 ▼ 34% vs 2024 (€ 218,642) Unfavourable step	▼ 34%
Equity	€ 29,011 Equity 2022: € 29,011 First fiscal year in the series	€ 29,128 Equity 2023: € 29,128 Unchanged (€ 29,011) Favourable step	€ 29,769 Equity 2024: € 29,769 ▲ 2% vs 2023 (€ 29,128) Favourable step	€ 30,800 Equity 2025: € 30,800 ▲ 3% vs 2024 (€ 29,769) Favourable step	▲ 3%
Total debts	€ 526,408 Total debts 2022: € 526,408 First fiscal year in the series	€ 632,100 Total debts 2023: € 632,100 ▲ 20% vs 2022 (€ 526,408) Unfavourable step	€ 1,719,874 Total debts 2024: € 1,719,874 ▲ 172% vs 2023 (€ 632,100) Unfavourable step	€ 1,945,987 Total debts 2025: € 1,945,987 ▲ 13% vs 2024 (€ 1,719,874) Unfavourable step	▲ 13%
Cash	€ 237,002 Cash 2022: € 237,002 First fiscal year in the series	€ 255,748 Cash 2023: € 255,748 ▲ 8% vs 2022 (€ 237,002) Favourable step	€ 287,118 Cash 2024: € 287,118 ▲ 12% vs 2023 (€ 255,748) Favourable step	€ 303,758 Cash 2025: € 303,758 ▲ 6% vs 2024 (€ 287,118) Favourable step	▲ 6%
Land & buildings	€ 6,593 Land & buildings 2022: € 6,593 First fiscal year in the series	€ 24,922 Land & buildings 2023: € 24,922 ▲ 278% vs 2022 (€ 6,593) Unchanged	€ 385,209 Land & buildings 2024: € 385,209 ▲ € 360,287 vs 2023 (€ 24,922) Unchanged	€ 384,584 Land & buildings 2025: € 384,584 Unchanged (€ 385,209) Unchanged
Retained profit	€ 10,411 Retained profit 2022: € 10,411 First fiscal year in the series	€ 10,528 Retained profit 2023: € 10,528 ▲ 1% vs 2022 (€ 10,411) Favourable step	€ 11,169 Retained profit 2024: € 11,169 ▲ 6% vs 2023 (€ 10,528) Favourable step	€ 12,200 Retained profit 2025: € 12,200 ▲ 9% vs 2024 (€ 11,169) Favourable step	▲ 9%
Dividend	€ 272,500 Dividend 2022: € 272,500 First fiscal year in the series	€ 298,000 Dividend 2023: € 298,000 ▲ 9% vs 2022 (€ 272,500) Unchanged	€ 218,000 Dividend 2024: € 218,000 ▼ 27% vs 2023 (€ 298,000) Unchanged	€ 142,500 Dividend 2025: € 142,500 ▼ 35% vs 2024 (€ 218,000) Unchanged	▼ 35%
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 0 Bank debt 2023: € 0 Unchanged (€ 0) Unchanged	€ 1,028,831 Bank debt 2024: € 1,028,831 Unchanged (€ 0) Unfavourable step	€ 1,260,657 Bank debt 2025: € 1,260,657 ▲ 23% vs 2024 (€ 1,028,831) Unfavourable step	▲ 23%
Balance sheet total	€ 555,418 Balance sheet total 2022: € 555,418 First fiscal year in the series	€ 661,228 Balance sheet total 2023: € 661,228 ▲ 19% vs 2022 (€ 555,418) Unchanged	€ 1,749,643 Balance sheet total 2024: € 1,749,643 ▲ 165% vs 2023 (€ 661,228) Unchanged	€ 1,976,788 Balance sheet total 2025: € 1,976,788 ▲ 13% vs 2024 (€ 1,749,643) Unchanged	▲ 13%
Employees (FTE)	2.9 Employees (FTE) 2022: 2.9 First fiscal year in the series	2.8 Employees (FTE) 2023: 2.8 ▼ 0.1 vs 2022 (2.9) Unchanged	2.8 Employees (FTE) 2024: 2.8 Unchanged (2.8) Unchanged	2.7 Employees (FTE) 2025: 2.7 ▼ 0.1 vs 2024 (2.8) Unchanged	▼ 0.1

Key figures of HAMPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to HAMPHARMA?

What happened at HAMPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 27, 2026 New annual accounts for financial year 2025: profit of € 143,531 (▼ 34% vs 2024). Source: NBB ↗
2004 Denayer Danielle BV became a director. NBB
Jul 1, 1982 New establishment in Tessenderlo-Ham. KBO
Jul 1, 1982 Start of the company according to the CBE. KBO

In short

From € 272,604 profit in 2022 to € 143,531 profit in 2025.

Paid € 39,312 in corporate taxes since 2022.

Best year ever: 2023, with € 298,117 profit.

On average € 186,700 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Denayer Danielle 99.6%

The stake of Denayer Danielle comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

HAMPHARMA

Behind HAMPHARMA is Denayer Danielle BV. The shares are held by Denayer Danielle (99.6%).

Directors

According to the 2025 annual accounts

Denayer Danielle BV

Director · represented by Danielle Denayer

since 2004

Shareholders

Denayer Danielle

99.6%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Bevrijdingsstraat 32

3945 Tessenderlo-Ham

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0423.277.613

VAT number

BE 0423.277.613

Registered office

Bevrijdingsstraat 32, 3945 Tessenderlo-Ham

Names & denominations

HAMPHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

1 July 1982

Peppol

Active · Active since 21 Sept 2025

Activities · NACE

Apothekers

Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗

HAMPHARMA

Financials

What happened to HAMPHARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions